Bacteria and cells as alternative nano-carriers for biomedical applications

References

• Hua S, Wu SY . Advances and Challenges in Nanomedicine. Vol. 9. Belgium: Frontiers in Pharmacology. 2019.
   Google Scholar
• Kim BYS, Rutka JT, Chan WCW. Nanomedicine. N Engl J Med. 2010;363:10.
   Web of Science ®Google Scholar
• Vallet-Regí M, Rámila A, Del Real RP, et al. A New Property of MCM-41: drug Delivery System. Chem Mater. 2001;13:4.
   Web of Science ®Google Scholar
• Vallet-Regí M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew Chem. 2007;46(4010):7548.
   Google Scholar
• Sau TK, Goia DV. Biomedical Applications of Gold Nanoparticles. United States: Springer; 2012.
   Google Scholar
• Vallet-Regí M. Our Contributions to Applications of Mesoporous Silica Nanoparticles. United States: Acta Biomaterialia, 2021; In Press.
   Google Scholar
• Bellah M, Christensen SM, Iqbal SM. Nanostructures for Medical Diagnosis. J Nanomater. 2012;1:21.
   Google Scholar
• Castillo RR, Colilla M, Vallet-Regí M. Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer. Expert Opin Drug Deliv. 2017;14(2):14.
   Web of Science ®Google Scholar
• Vallet-Regí M, González B, Izquierdo-Barba I. Nanomaterials as Promising Alternative in the Infection Treatment. Int J Mol Sci. 2019;20(15):18.
   Web of Science ®Google Scholar
• Baeza A, Vallet-Regí M. Mesoporous Silica Nanoparticles as Theranostic Antitumoral Nanomedicines. Pharmaceutics. 2020;12(10):16.
   Web of Science ®Google Scholar
• Zhao P, Li N, Astruc D. State of the art in gold nanoparticle synthesis. Coord Chem Rev. 2013;257:28.
   Web of Science ®Google Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102.
   PubMed Web of Science ®Google Scholar
• Vallet-Regí M, Colilla M, Izquierdo-Barba I, et al. Mesoporous Silica Nanoparticles for Drug Delivery: current Insights. Molecules. 2017;23(1):47.
   Web of Science ®Google Scholar
• Álvarez E, Estévez M, Jiménez-Jiménez C, et al. A versatile multicomponent mesoporous silica nanosystem with dual antimicrobial and osteogenic effects. Acta Biomater. 2021;136:570–581.
   PubMed Web of Science ®Google Scholar
• Cedervall T, Lynch I, Lindman S, et al. Understanding the nanoparticle-protein Corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proceedings of the National Academy of Sciences (PNAS). 2007. 104: p. 6.
   Web of Science ®Google Scholar
• Ke PC, Lin S, Parak WJ, et al. A Decade of the Protein Corona. ACS Nano. 2017;11(12):4.
   Web of Science ®Google Scholar
• Monopoli M, Aberg C, Salvati A, et al. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol. 2012;7:8.
   Web of Science ®Google Scholar
• Ahsan SA, Rao CM, Ahmad MF. Nanoparticle-Protein Interaction: the Significance and Role of Protein Corona. Cellular and Molecular Toxicology of Nanoparticles - Advances. 2018;1:24.
   Google Scholar
• Nguyen VH, Lee B-J. Protein Corona: a new approach for nanomedicine design. Int J Nanomedicine. 2017;12:15.
   PubMed Web of Science ®Google Scholar
• Zanganeh S, Spitler R, Erfanzadeh M, et al. Protein Corona. Opportunities and Challlenges. Int J Biochem Cell Biol. 2016;75:5.
   Web of Science ®Google Scholar
• Lundqvist M, Stigler J, Elia G, et al. Nanoparticle size and surface properties determine the protein Corona with possible implications for biological impacts. Proceedings of the National Academy of Sciences (PNAS). 2008. 105( 38): p. 6.
   Web of Science ®Google Scholar
• Liu W, Rose J, Plantevin S, et al. Protein Corona formation for nanomaterials and proteins of a similar size: hard or soft Corona? Nanoscale. 2013;5:11.
   Web of Science ®Google Scholar
• Caracciolo G, Pozzi D, Capriotti AL, et al. Lipid composition: a “key” factor for the rational manipulation of the liposome-protein Corona by liposome design. The Royal Society of Chemistry Advances. 2015;5. 9.
   Web of Science ®Google Scholar
• Caracciolo G. Clinically approved liposomal nanomedicines: lessons learned from the biomolecular Corona. Nanoscale. 2018;10:6.
   Web of Science ®Google Scholar
• Charbgoo F, Nejabat M, Abnous K, et al. Gold nanoparticle should understand protein Corona for being a clinical nanomaterial. J Control Release. 2018;272:15.
   Web of Science ®Google Scholar
• Hadjdemetriou M, McAdam, S, Garner, G, et al. The Human In Vivo Biomolecule Corona onto PEGylated Liposomes: a Proof-of-Concept Clinical Study. Adv Mater. 2019;31(4):e1803335.
   Web of Science ®Google Scholar
• Pérez JMM; María Vallet-Regí. GIBI. Bacteria and cells as ”cabs” for drug-loaded nanoparticles. 2021. https://www.youtube.com/watch?v=Wsbcpt-cE3E
   Google Scholar
• Yoo J-W, Irvine DJ, Discher DE, et al. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov. 2011;10(7):521–535.
   PubMed Web of Science ®Google Scholar
• Shende P, Basarkar V. Recent trends and advances in microbe-based drug delivery systems. Daru. 2019;27(2):799–809.
   PubMed Web of Science ®Google Scholar
• Hosseinidoust Z, Mostaghaci B, Yasa O, et al. Bioengineered and biohybrid bacteria-based systems for drug delivery. Adv Drug Deliv Rev. 2016;106:27–44. Pt A.
   PubMed Web of Science ®Google Scholar
• Baquero F, Nombela C. The microbiome as a human organ. Clin Microbiol Infect. 2012;18:2–4.
   PubMed Web of Science ®Google Scholar
• The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–214.
   PubMed Web of Science ®Google Scholar
• Sowa Y, Rowe AD, Leake MC, et al. Direct observation of steps in rotation of the bacterial flagellar motor. Nature. 2005;437(7060):916–919.
   PubMed Web of Science ®Google Scholar
• Martel S. Bacterial microsystems and microrobots. Biomed Microdevices. 2012;14(6):1033–1045.
   PubMed Web of Science ®Google Scholar
• Storz G, Hengge R. Bacterial Stress Responses. 2nd ed. A.S.f.M. United States: ASM Press; 2010.
   Google Scholar
• Lim D, Song M. Development of bacteria as diagnostics and therapeutics by genetic engineering. J Microbiol. 2019;57(8):637–643.
   PubMed Web of Science ®Google Scholar
• Lutz H, Hu S, Dinh P-U, et al. Cells and cell derivatives as drug carriers for targeted delivery. Medicine in Drug Discovery. 2019;3. 100014.
   Google Scholar
• Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev. 2012;64(8):739–748.
   PubMed Web of Science ®Google Scholar
• Hu YL, Fu Y-H, Tabata Y, et al. Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. J Control Release. 2010;147(2):154–162.
   PubMed Web of Science ®Google Scholar
• Wu GD, Lewis JD. Analysis of the Human Gut Microbiome and Association With Disease. Clin Gastroenterol Hepatol. 2013;11(7):774–777.
   PubMed Web of Science ®Google Scholar
• Belkaid Y, Hand TW. Role of the Microbiota in Immunity and Inflammation. Cell. 2014;157(1):121–141.
   PubMed Web of Science ®Google Scholar
• Islam SU. Clinical Uses of Probiotics. Medicine (Baltimore). 2016;95(5):e2658.
   PubMed Web of Science ®Google Scholar
• Wieërs G, Belkhir L, Enaud R, et al. How Probiotics Affect the Microbiota. Front Cell Infect Microbiol. 2019;9:454.
   PubMed Web of Science ®Google Scholar
• Sharifi-Rad J, Rodrigues CF. Probiotics: versatile Bioactive Components in Promoting Human Health. Medicina (Kaunas). 2020; 56(9):43.
   Web of Science ®Google Scholar
• Dimidi E, Christodoulides S, Scott SM, et al. Mechanisms of Action of Probiotics and the Gastrointestinal Microbiota on Gut Motility and Constipation. Adv Nutr. 2017;8(3):484–494.
   PubMed Web of Science ®Google Scholar
• Valdés-Varela L, Gueimonde M, Ruas-Madiedo P. Probiotics for Prevention and Treatment of Clostridium difficile Infection. Adv Exp Med Biol. 2018;1050:161–176.
   PubMed Web of Science ®Google Scholar
• Allen SJ, Martinez EG, Gregorio GV, et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;11(11): Cd003048.
   Google Scholar
• Metchnikoff E. The prolongation of life: optimistic studies. United Kingdom: Heinemann. 1908.
   Google Scholar
• Podolsky SH. Metchnikoff and the microbiome. Lancet. 2012;380(9856):1810–1811.
   PubMed Web of Science ®Google Scholar
• Mackowiak P. Recycling Metchnikoff: probiotics, the Intestinal Microbiome and the Quest for Long Life. Front Public Health. 2013;1: 1–3.
   PubMedGoogle Scholar
• Prescott SL. History of medicine: origin of the term microbiome and why it matters. Human Microbiome Journal. 2017;4:24–25.
   Google Scholar
• Ozen M, Dinleyici EC. The history of probiotics: the untold story. Benef Microbes. 2015;6(2):159–165.
   PubMed Web of Science ®Google Scholar
• Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. 2000;30(1):54–60.
   PubMed Web of Science ®Google Scholar
• Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2011;1(45 Suppl):S149–53.
   Google Scholar
• Bizzini B, Pizzo G, Scapagnini G, et al. Probiotics and oral health. Curr Pharm Des. 2012;18(34):5522–5531.
   PubMed Web of Science ®Google Scholar
• Yari M, Ghoshoon MB, Vakili B, et al. Therapeutic Enzymes: applications and Approaches to Pharmacological Improvement. Curr Pharm Biotechnol. 2017;18(7):531–540.
   PubMed Web of Science ®Google Scholar
• Drăgănescu M, Carmocan C. Hormone Therapy in Breast Cancer. Chirurgia (Bucur). 2017;112(4):413–417.
   PubMed Web of Science ®Google Scholar
• Casarini L, Crépieux P, Reiter E, et al. FSH for the Treatment of Male Infertility. Int J Mol Sci. 2020;21(7):2270.
   Web of Science ®Google Scholar
• Roland KL, Brenneman KE. Salmonella as a vaccine delivery vehicle. Expert Rev Vaccines. 2013;12(9):1033–1045.
   PubMed Web of Science ®Google Scholar
• Bruhn KW, Craft N, Miller JF. Listeria as a vaccine vector. Microbes Infect. 2007;9(10):1226–1235.
   PubMed Web of Science ®Google Scholar
• Somerville JE Jr., Cassiano L, Bainbridge B, et al. A novel Escherichia coli lipid A mutant that produces an antiinflammatory lipopolysaccharide. J Clin Invest. 1996;97(2):359–365.
   PubMed Web of Science ®Google Scholar
• Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol. 1999;17(1):37–41.
   PubMed Web of Science ®Google Scholar
• Mohr KI. History of Antibiotics Research. Curr Top Microbiol Immunol. 2016;398:237–272.
   PubMed Web of Science ®Google Scholar
• Duong MT, Qin Y, You S-H, et al. Bacteria-cancer interactions: bacteria-based cancer therapy. Exp Mol Med. 2019;51(12):1–15.
   PubMedGoogle Scholar
• Duan FF, Liu JH, March JC. Engineered Commensal Bacteria Reprogram Intestinal Cells Into Glucose-Responsive Insulin-Secreting Cells for the Treatment of Diabetes. Diabetes. 2015;64(5):1794–1803.
   PubMed Web of Science ®Google Scholar
• Kearns DB. A field guide to bacterial swarming motility. Nature Rev Microbiol. 2010;8(9):634–644.
   PubMed Web of Science ®Google Scholar
• Proft T, Baker EN. Pili in Gram-negative and Gram-positive bacteria - structure, assembly and their role in disease. Cell Mol Life Sci. 2009;66(4):613–635.
   PubMed Web of Science ®Google Scholar
• Danne C, Dramsi S. Pili of gram-positive bacteria: roles in host colonization. Res Microbiol. 2012;163(9–10):645–658.
   PubMed Web of Science ®Google Scholar
• Goldstein RA, Soyer OS. Evolution of Taxis Responses in Virtual Bacteria: non-Adaptive Dynamics. PLoS Comput Biol. 2008;4(5):e1000084.
   PubMed Web of Science ®Google Scholar
• Krell T, Lacal J, Muñoz-Martinez F, et al. Diversity at its best: bacterial taxis. Environ Microbiol. 2011;13(5):1115–1124.
   PubMed Web of Science ®Google Scholar
• Gu H. Role of Flagella in the Pathogenesis of Helicobacter pylori. Curr Microbiol. 2017;74(7):863–869.
   PubMed Web of Science ®Google Scholar
• Taniguchi SI, Shimatani Y, Fujimori M. Tumor-Targeting Therapy Using Gene-Engineered Anaerobic-NonpathogenicBifidobacterium longum. In: Hoffman RM, editor. Bacterial Therapy of Cancer: methods and Protocols. New York: Springer New York; 2016. p. 49–60.
   Google Scholar
• Pastrana E. Optogenetics: controlling cell function with light. Nat Methods. 2011;8(1):24–25.
   Web of Science ®Google Scholar
• Motta-Mena LB, Reade A, Mallory MJ, et al. An optogenetic gene expression system with rapid activation and deactivation kinetics. Nat Chem Biol. 2014;10(3):196–202.
   PubMed Web of Science ®Google Scholar
• Polstein LR, Gersbach CA. A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nat Chem Biol. 2015;11(3):198–200.
   PubMed Web of Science ®Google Scholar
• Olson EJ, Tabor JJ. Optogenetic characterization methods overcome key challenges in synthetic and systems biology. Nat Chem Biol. 2014;10(7):502–511.
   PubMed Web of Science ®Google Scholar
• Faivre D, Schüler D. Magnetotactic Bacteria and Magnetosomes. Chem Rev. 2008;108(11):4875–4898.
   PubMed Web of Science ®Google Scholar
• Felfoul O, Martel S. Assessment of navigation control strategy for magnetotactic bacteria in microchannel: toward targeting solid tumors. Biomed Microdevices. 2013;15(6):1015–1024.
   PubMed Web of Science ®Google Scholar
• Martel S. Towards MRI-controlled ferromagnetic and MC-1 magnetotactic bacterial carriers for targeted therapies in arteriolocapillar networks stimulated by tumoral angiogenesis. Conf Proc IEEE Eng Med Biol Soc. 2006;2006:3399–3402.
   PubMedGoogle Scholar
• Tang YS, Wang D, Zhou C, et al. Bacterial magnetic particles as a novel and efficient gene vaccine delivery system. Gene Ther. 2012;19(12):1187–1195.
   PubMed Web of Science ®Google Scholar
• Carlsen RW, Edwards MR, Zhuang J, et al. Magnetic steering control of multi-cellular bio-hybrid microswimmers. Lab Chip. 2014;14(19):3850–3859.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lin Y, Gillies RJ. Tumor pH and Its Measurement. J Nucl Med. 2010;51(8):1167–1170.
   PubMed Web of Science ®Google Scholar
• Zhuang J, Wright Carlsen R, Sitti M. pH-Taxis of Biohybrid Microsystems. Sci Rep. 2015;5(1):11403.
   PubMedGoogle Scholar
• Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4(6):437–447.
   PubMed Web of Science ®Google Scholar
• Villegas MR, Baeza A, Noureddine A, et al. Multifunctional Protocells for Enhanced Penetration in 3D Extracellular Tumoral Matrices. Chem Mater. 2018;30(1):112–120.
   Web of Science ®Google Scholar
• Chen CY, Chen C-F, Yi Y, et al. Construction of a microrobot system using magnetotactic bacteria for the separation of Staphylococcus aureus. Biomed Microdevices. 2014;16(5):761–770.
   PubMed Web of Science ®Google Scholar
• Anderson JC, Clarke EJ, Arkin AP, et al. Environmentally Controlled Invasion of Cancer Cells by Engineered Bacteria. J Mol Biol. 2006;355(4):619–627.
   PubMed Web of Science ®Google Scholar
• Stritzker J, Weibel S, Hill PJ, et al. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol. 2007;297(3):151–162.
   PubMed Web of Science ®Google Scholar
• Xiang S, Fruehauf J, Li CJ. Short hairpin RNA–expressing bacteria elicit RNA interference in mammals. Nat Biotechnol. 2006;24(6):697–702.
   PubMed Web of Science ®Google Scholar
• Seavey MM, Pan Z-K, Maciag PC, et al. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin Cancer Res. 2009;15(3):924–932.
   PubMed Web of Science ®Google Scholar
• Du ZQ, Wang JY. A novel lumazine synthase molecule from Brucella significantly promotes the immune-stimulation effects of antigenic protein. Genet Mol Res. 2015;14(4):13084–13095.
   PubMed Web of Science ®Google Scholar
• Barbé S, Mellaert LV, Theys J, et al. Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment. FEMS Microbiol Lett. 2005;246(1):67–73.
   PubMed Web of Science ®Google Scholar
• Feltis BA, Miller JS, Sahar DE, et al. Liver and Circulating NK1.1+CD3− Cells Are Increased in Infection with Attenuated Salmonella typhimurium and Are Associated with Reduced Tumor in Murine Liver Cancer. J Surg Res. 2002;107(1):101–107.
   PubMed Web of Science ®Google Scholar
• Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol. 2014;5(172):1–17.
   Web of Science ®Google Scholar
• Pálffy R, Gardlik R, Hodosy J, et al. Bacteria in gene therapy: bactofection versus alternative gene therapy. Gene Ther. 2006;13(2):101–105.
   PubMed Web of Science ®Google Scholar
• Schaffner W. Direct transfer of cloned genes from bacteria to mammalian cells Proceedings of the National Academy of Sciences. 77( 4): p. 2163–2167.
   PubMed Web of Science ®Google Scholar
• Yazawa K, Fujimori M, Nakamura T, et al. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat. 2001;66(2):165–170.
   PubMed Web of Science ®Google Scholar
• Okuda K, Wada Y, Shimada M. Recent Developments in Preclinical DNA Vaccination. Vaccines (Basel). 2014;2(1):89–106.
   PubMedGoogle Scholar
• Sciaranghella G, Lakhashe S, Ayash-Rashkovsky S, et al. A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly. Vaccine. 2011;29(3):476–486.
   PubMed Web of Science ®Google Scholar
• Montanaro J, Inic-Kanada A, Ladurner A, et al. Escherichia coli Nissle 1917 bacterial ghosts retain crucial surface properties and express chlamydial antigen: an imaging study of a delivery system for the ocular surface. Drug Des Devel Ther. 2015;9:3741–3754.
   PubMed Web of Science ®Google Scholar
• Kudela P, Koller VJ, Lubitz W. Bacterial ghosts (BGs)—Advanced antigen and drug delivery system. Vaccine. 2010;28(36):5760–5767.
   PubMed Web of Science ®Google Scholar
• Langemann T, Koller VJ, Muhammad A, et al. The bacterial ghost platform system. Bioengineered Bugs. 2010;1(5):326–336.
   PubMedGoogle Scholar
• Tabrizi CA, Walcher P, Mayr UB, et al. Bacterial ghosts – biological particles as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol. 2004;15(6):530–537.
   PubMed Web of Science ®Google Scholar
• Huter V, Szostak MP, Gampfer J, et al. Bacterial ghosts as drug carrier and targeting vehicles. J Control Release. 1999;61(1):51–63.
   PubMed Web of Science ®Google Scholar
• Paukner S, Kohl G, Jalava K, et al. Sealed bacterial ghosts–novel targeting vehicles for advanced drug delivery of water-soluble substances. J Drug Target. 2003;11(3):151–161.
   PubMed Web of Science ®Google Scholar
• Lin W-C, Lien C-C, Yeh H-J, et al. Bacterial cellulose and bacterial cellulose–chitosan membranes for wound dressing applications. Carbohydr Polym. 2013;94(1):603–611.
   PubMed Web of Science ®Google Scholar
• Claesen J, Fischbach MA. Synthetic Microbes As Drug Delivery Systems. ACS Synth Biol. 2015;4(4):358–364.
   PubMed Web of Science ®Google Scholar
• Dong Z-M, Jin X, Zhao G-C. Amplified QCM biosensor for type IV collagenase based on collagenase-cleavage of gold nanoparticles functionalized peptide. Biosens Bioelectron. 2018;106:111–116.
   PubMed Web of Science ®Google Scholar
• Suh S, Jo A, Traore MA, et al. Nanoscale Bacteria-Enabled Autonomous Drug Delivery System (NanoBEADS) Enhances Intratumoral Transport of Nanomedicine. Advance Science (Weinh). 2019;6(3):1801309.
   PubMedGoogle Scholar
• Moreno VM, Álvarez E, Izquierdo-Barba I, et al. Bacteria as Nanoparticles Carrier for Enhancing Penetration in a Tumoral Matrix Model. Adv Mater Interfaces. 2020;7(11):1901942.
   Web of Science ®Google Scholar
• Zargar SM, Hafshejani DK, Eskandarinia A, et al. A Review of Controlled Drug Delivery Systems Based on Cells and Cell Membranes. J Med Signals Sens. 2019;9(3):181–189.
   PubMedGoogle Scholar
• Hart GD. Descriptions of blood and blood disorders before the advent of laboratory studies. Br J Haematol. 2001;115(4):719–728.
   PubMed Web of Science ®Google Scholar
• Hook R. Micrographia. United Kingdom: Echo Library. 1665.
   Google Scholar
• Becker AJ, Mc CE, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature. 1963;197:452–454.
   PubMed Web of Science ®Google Scholar
• McCulloch EA, Till JE. Perspectives on the properties of stem cells. Nat Med. 2005;11(10):1026–1028.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell. 2006;126(4):663–676.
   PubMed Web of Science ®Google Scholar
• Hamidi M, Zarrin A, Foroozesh M, et al. Applications of carrier erythrocytes in delivery of biopharmaceuticals. J Control Release. 2007;118(2):145–160.
   PubMed Web of Science ®Google Scholar
• Muzykantov VR. Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin Drug Deliv. 2010;7(4):403–427.
   PubMed Web of Science ®Google Scholar
• Gopal V, Kumar AR, Usha AN, et al. Effective drug targeting by Erythrocytes as Carrier Systems. Current Trends in Biotechnology and Pharmacy. 2007;1. 18–33.
   Google Scholar
• Chambers E, Mitragotri S. Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes. J Control Release. 2004;100(1):111–119.
   PubMed Web of Science ®Google Scholar
• Domenech C, Thomas X, Chabaud S, et al. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol. 2011;153(1):58–65.
   PubMed Web of Science ®Google Scholar
• Chambers E, Mitragotri S. Long circulating nanoparticles via adhesion on red blood cells: mechanism and extended circulation. Exp Biol Med (Maywood). 2007;232(7):958–966.
   PubMed Web of Science ®Google Scholar
• Sun Y, Su J, Liu G, et al. Advances of blood cell-based drug delivery systems. Eur J Pharm Sci. 2017;96:115–128.
   PubMed Web of Science ®Google Scholar
• Xu P, Zuo H, Chen B, et al. Doxorubicin-loaded platelets as a smart drug delivery system: an improved therapy for lymphoma. Sci Rep. 2017;7:42632.
   PubMed Web of Science ®Google Scholar
• Xu P, Zuo H, Zhou R, et al. Doxorubicin-Loaded Platelets Conjugated with Anti-CD22 Mabs: a Novel Targeted Delivery System for B-Cell Lymphoma Treatment with Cardiac Avoidance. Blood. 2017;130:1535.
   PubMed Web of Science ®Google Scholar
• Modery-Pawlowski CL, Master AM, Pan V, et al. A platelet-mimetic paradigm for metastasis-targeted nanomedicine platforms. Biomacromolecules. 2013;14(3):910–919.
   PubMed Web of Science ®Google Scholar
• Dou H, Destache CJ, Morehad JR, et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood. 2006;108(8):2827–2835.
   PubMed Web of Science ®Google Scholar
• Klyachko NL, Polak R, Haney MJ, et al. Macrophages with cellular backpacks for targeted drug delivery to the brain. Biomaterials. 2017;140:79–87.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang M, Tang W, et al. Nanoparticle-Laden Macrophages for Tumor-Tropic Drug Delivery. Advanced Materials. 2018;35:e1805557.
   Google Scholar
• Dong X, Chu D, Wang Z. Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites. Theranostics. 2017;7(3):751–763.
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, King MR. Leukocytes as carriers for targeted cancer drug delivery. Expert Opin Drug Deliv. 2015;12(3):375–392.
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16(7):431–446.
   PubMed Web of Science ®Google Scholar
• Chu D, Dhong X, Shi X, et al. Neutrophil-Based Drug Delivery Systems. Advanced Materials. 2018;322:e1706245
   Google Scholar
• Amulic B, Cazalet C, Hayes GL, et al. Neutrophil function: from mechanisms to disease. Annu Rev Immunol. 2012;30:459–489.
   PubMed Web of Science ®Google Scholar
• Xue J, Zhao Z, Zhang L, et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat Nanotechnol. 2017;12(7):692–700.
   PubMed Web of Science ®Google Scholar
• Ju C, Wen Y, Zhang L, et al. Neoadjuvant Chemotherapy Based on Abraxane/Human Neutrophils Cytopharmaceuticals with Radiotherapy for Gastric Cancer. Small. 2019;15(5):e1804191.
   PubMed Web of Science ®Google Scholar
• Yu H, Yang Z, Li F, et al. Cell-mediated targeting drugs delivery systems. Drug Deliv. 2020;27(1):1425–1437.
   PubMed Web of Science ®Google Scholar
• Stephan MT, Moon JJ, Um SH, et al. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med. 2010;16(9):1035–1041.
   PubMed Web of Science ®Google Scholar
• Huang B, Abraham WD, Zheng Y, et al. Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Sci Transl Med. 2015;7(291):291ra94.
   PubMed Web of Science ®Google Scholar
• Mahla RS. Stem Cells Applications in Regenerative Medicine and Disease Therapeutics. Int J Cell Biol. 2016;2016:6940283.
   PubMedGoogle Scholar
• Stuckey DW, Shah K. Stem cell-based therapies for cancer treatment: separating hope from hype. Nat Rev Cancer. 2014;14(10):683–691.
   PubMed Web of Science ®Google Scholar
• Dembinski JL, Wilson SM, Spaeth EL, et al. Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer. Cytotherapy. 2013;15(1):20–32.
   PubMed Web of Science ®Google Scholar
• Sasportas LS, Kasmieh R, Wakimoto H, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A. 2009;106(12):4822–4827.
   PubMed Web of Science ®Google Scholar
• Roger M, Clavreul A, Venier-Julienne M-C, et al. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials. 2010;31(32):8393–8401.
   PubMed Web of Science ®Google Scholar
• Miller DM, Gulbis JM. Engineering protocells: prospects for self-assembly and nanoscale production-lines. Life (Basel). 2015;5(2):1019–1053.
   PubMedGoogle Scholar
• Butler KS, Durfee PN, Theron C, et al. Protocells: modular Mesoporous Silica Nanoparticle-Supported Lipid Bilayers for Drug Delivery. Small. 2016;12(16):2173–2185.
   PubMed Web of Science ®Google Scholar
• Luchini A, Vitiello G. Understanding the Nano-bio Interfaces: lipid-Coatings for Inorganic Nanoparticles as Promising Strategy for Biomedical Applications. Front Chem. 2019;7(343):1–16.
   Web of Science ®Google Scholar
• Durfee PN, Lin Y-S, Dunphy DR, et al. Mesoporous Silica Nanoparticle-Supported Lipid Bilayers (Protocells) for Active Targeting and Delivery to Individual Leukemia Cells. ACS Nano. 2016;10(9):8325–8345.
   PubMed Web of Science ®Google Scholar
• Mahmoudi M, Sant S, Wang B, et al. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev. 2011;63(1):24–46.
   PubMed Web of Science ®Google Scholar
• Zhang H. Erythrocytes in nanomedicine: an optimal blend of natural and synthetic materials. Biomater Sci. 2016;4(7):1024–1031.
   PubMed Web of Science ®Google Scholar
• Marczak A, Kowalczyk A, Wrzesien-Kus A, et al. Interaction of doxorubicin and idarubicin with red blood cells from acute myeloid leukaemia patients. Cell Biol Int. 2006;30(2):127–132.
   PubMed Web of Science ®Google Scholar
• Fang RH, Hu C-M, Luk BT, et al. Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery. Nano Lett. 2014;14(4):2181–2188.
   PubMed Web of Science ®Google Scholar
• Xuan M, Shao J, Dai L, et al. Macrophage Cell Membrane Camouflaged Mesoporous Silica Nanocapsules for In Vivo Cancer Therapy. Adv Healthc Mater. 2015;4(11):1645–1652.
   PubMed Web of Science ®Google Scholar
• Paris JL, De la Torre P, Manzano M, et al. Decidua-derived mesenchymal stem cells as carriers of mesoporous silica nanoparticles. In vitro and in vivo evaluation on mammary tumors. Acta Biomater. 2016;33:275–282.
   PubMed Web of Science ®Google Scholar
• Tang L, Zheng Y, Bandeira Melo M, et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol. 2018;36(8):707–716.
   PubMed Web of Science ®Google Scholar